Plasma stability assay

NR Nathan T. Ross
FL Felix Lohmann
SC Seth Carbonneau
AF Aleem Fazal
WW Wilhelm A. Weihofen
SG Scott Gleim
MS Michael Salcius
FS Frederic Sigoillot
MH Martin Henault
SC Sarah H. Carl
JR Juan B. Rodríguez-Molina
HM Howard R. Miller
SB Scott M. Brittain
JM Jason Murphy
MZ Mark Zambrowski
GB Geoffrey Boynton
YW Yuan Wang
AC Aye Chen
GM Gregory J. Molind
JW Johannes H. Wilbertz
CA Caroline G. Artus-Revel
MJ Min Jia
FA Favour A. Akinjiyan
JT Jonathan Turner
JK Judith Knehr
WC Walter Carbone
SS Sven Schuierer
JR John S. Reece-Hoyes
KX Kevin Xie
CS Chitra Saran
EW Eric T. Williams
GR Guglielmo Roma
MS Matt Spencer
JJ Jeremy Jenkins
EG Elizabeth L. George
JT Jason R. Thomas
GM Gregory Michaud
MS Markus Schirle
JT John Tallarico
LP Lori A. Passmore
JC Jeffrey A. Chao
RB Rohan E.J. Beckwith
request Request a Protocol
ask Ask a question
Favorite

Plasma stability assays were conducted with final concentrations of 99% plasma, 1% DMSO, and 5 μM compound. Incubations occurred in EDTA-treated plasma (BioreclamationIVT) from five species – C57BL/6 mouse, Sprague Dawley rat, Beagle dog, Cynomolgus monkey, and human. Time points up to 4 h were collected and quenched on ice with 6X volume of acetonitrile containing an internal standard, 100 ng mL-1 glyburide. Samples were vortexed then centrifuged to precipitate protein. A 6:5 ratio of water:supernatant were mixed for injection on a Sciex 4000 with a TSI source in positive mode with a source temperature, spray voltage, gas 1, gas 2, CAD gas, and curtain gas settings of 500, 5500, 60, 60, 10, and 30, respectively. Transitions for 1, 2, and glyburide were 524.2 > 84.1, 496.4 > 127.1, and 494.2 > 168.8, respectively, with declustering potentials of 70, 100, and 70 V, respectively, and collision energies of 45, 65, and 40 V, respectively. An Agilent liquid chromatography system used a ACE C18 30x2.0 mm and 3 μm column (Advanced Chromatography Technologies Ltd.) with solvents A and B containing 0.1% formic acid in water (A) and acetonitrile (B) at a flow rate of 0.7 mL min-1 with a gradient profile of 2% B from 0 to 0.5 min, an increase from 2% to 98% B from 0.5 to 2 min, 98% B from 2 to 2.5 min, a decrease from 98% to 2% B from 2.5 to 2.6 min, and 2% B from 2.6 to 3 min.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A